+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Foot Ulcers - Pipeline Review, H2 2019

  • ID: 4901344
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 165 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Alan Laboratories Inc
  • Biofilm Pharma
  • CytoTools AG
  • Imstem Biotechnology Inc
  • NovaLead Pharma Pvt Ltd
  • RHEACELL GmbH & Co KG
  • MORE
Diabetic Foot Ulcers - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2019, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 15, 10, 17, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alan Laboratories Inc
  • Biofilm Pharma
  • CytoTools AG
  • Imstem Biotechnology Inc
  • NovaLead Pharma Pvt Ltd
  • RHEACELL GmbH & Co KG
  • MORE
Introduction
Report Coverage
Diabetic Foot Ulcers - Overview
Diabetic Foot Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Foot Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
Alan Laboratories Inc
Anterogen Co Ltd
Aposcience AG
Aprogen Inc
APstem Therapeutics Inc
AptaBio Therapeutics Inc
Aurealis Therapeutics AG
Biofilm Pharma
Biotherapy Services Ltd
Blue Blood Biotech Corp
Canton Biotechnologies Inc
CardioVascular BioTherapeutics Inc
Celularity Inc
Chiesi Farmaceutici SpA
CSA Biotechnologies LLC
Cynata Therapeutics Ltd
CytoTools AG
Destiny Pharma Plc
Energenesis Biomedical Co Ltd
EyeGene Inc
FirstString Research Inc
Genentech Inc
Helixmith Co Ltd
Hoth Therapeutics Inc
Human Stem Cells Institute
Imstem Biotechnology Inc
Lakewood-Amedex Inc
Liminal BioSciences Inc
Mallinckrodt Plc
MangoGen Pharma Inc
MediWound Ltd
Mirae Cell Bio Co Ltd
NovaLead Pharma Pvt Ltd
OliX Pharmaceuticals Inc
Orbsen Therapeutics Ltd
Pherecydes Pharma SA
Promore Pharma AB
QBiotics Ltd
Remedor Biomed Ltd
RHEACELL GmbH & Co KG
Riptide Bioscience Inc
Serodus ASA
Shionogi & Co Ltd
Sinobioway Biomedical Co Ltd
Stempeutics Research Pvt Ltd
Suzhou Kintor Pharmaceutical Inc
TechnoPhage SA
TGV-Inhalonix Inc
Topadur Pharma AG
Transwell Biotech Co Ltd
USV Pvt Ltd
Vasomune Inc
Xenexus Pharmaceuticals Pty Ltd
ZZ Biotech LLC
Diabetic Foot Ulcers - Drug Profiles
Diabetic Foot Ulcers - Dormant Projects
Diabetic Foot Ulcers - Discontinued Products
Diabetic Foot Ulcers - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Diabetic Foot Ulcers, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Diabetic Foot Ulcers - Pipeline by Alan Laboratories Inc, H2 2019
Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, H2 2019
Diabetic Foot Ulcers - Dormant Projects, H2 2019
Diabetic Foot Ulcers - Dormant Projects, H2 2019 (Contd..1), H2 2019
Diabetic Foot Ulcers - Dormant Projects, H2 2019 (Contd..2), H2 2019
Diabetic Foot Ulcers - Dormant Projects, H2 2019 (Contd..3), H2 2019
Diabetic Foot Ulcers - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Diabetic Foot Ulcers, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alan Laboratories Inc
  • Anterogen Co Ltd
  • Aposcience AG
  • Aprogen Inc
  • APstem Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Aurealis Therapeutics AG
  • Biofilm Pharma
  • Biotherapy Services Ltd
  • Blue Blood Biotech Corp
  • Canton Biotechnologies Inc
  • CardioVascular BioTherapeutics Inc
  • Celularity Inc
  • Chiesi Farmaceutici SpA
  • CSA Biotechnologies LLC
  • Cynata Therapeutics Ltd
  • CytoTools AG
  • Destiny Pharma Plc
  • Energenesis Biomedical Co Ltd
  • EyeGene Inc
  • FirstString Research Inc
  • Genentech Inc
  • Helixmith Co Ltd
  • Hoth Therapeutics Inc
  • Human Stem Cells Institute
  • Imstem Biotechnology Inc
  • Lakewood-Amedex Inc
  • Liminal BioSciences Inc
  • Mallinckrodt Plc
  • MangoGen Pharma Inc
  • MediWound Ltd
  • Mirae Cell Bio Co Ltd
  • NovaLead Pharma Pvt Ltd
  • OliX Pharmaceuticals Inc
  • Orbsen Therapeutics Ltd
  • Pherecydes Pharma SA
  • Promore Pharma AB
  • QBiotics Ltd
  • Remedor Biomed Ltd
  • RHEACELL GmbH & Co KG
  • Riptide Bioscience Inc
  • Serodus ASA
  • Shionogi & Co Ltd
  • Sinobioway Biomedical Co Ltd
  • Stempeutics Research Pvt Ltd
  • Suzhou Kintor Pharmaceutical Inc
  • TechnoPhage SA
  • TGV-Inhalonix Inc
  • Topadur Pharma AG
  • Transwell Biotech Co Ltd
  • USV Pvt Ltd
  • Vasomune Inc
  • Xenexus Pharmaceuticals Pty Ltd
  • ZZ Biotech LLC
Note: Product cover images may vary from those shown
Adroll
adroll